1432-1433 / 2063
Phase Agent
Site
Target
I
Sorafenib
SCCHN
Raf/MEK/ERK
I
Sorafenib
Thorax, abdomen, pelvis
Raf/MEK/ERK
I
Sorafenib
Hepatocellular carcinoma
Raf/MEK/ERK
I
Sunitinib
brain met
PDGFR/VEGFR/KIT
I/II
Sorafenib
bone mets, RCC
Raf/MEK/ERK
I/II
Sorafenib
Unresectable liver mets
Raf/MEK/ERK
I/II
Sorafenib
Cervix
Raf/MEK/ERK
I/II
Nimotuzumab NSCLC
EGFR
II
Erlotinib
NSCLC
EGFR
II
Nimotuzumab Brain met NSCLC
EGFR
II
Vandetanib
SCCHN
VEGFR, EGFR
II/III
CDX-110
GBM
EGFRvIII
III
Cetuximab
HN
EGFR
III
Cetuximab
Esophageal
EGFR
III
Panitumumab SCCHN
EGFR
III
Avastin
glioblastoma
VEGF-A
Canadian clinical trials with RT